SCHEMBL266389

SCHEMBL266389

CC(=O)CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
FFAR1 O14842 1/20 0.54
PDPK1 O15530 1/20 0.53
TAAR1 Q96RJ0 1/20 0.52
PLAAT3 P53816 1/20 0.51
PLAAT5 Q96KN8 1/20 0.51
PLAAT2 Q9NWW9 1/20 0.51
PLAAT4 Q9UL19 1/20 0.51
HRH3 Q9Y5N1 2/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
MAPT P10636 1/20 0.50
MAOB P27338 2/20 0.47
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
DAO P14920 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SRD5A2 P31213 1/20 0.45
UTS2R Q9UKP6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653307 0.95 MAOB (0.54) ALDH1A1FFAR1PDPK1TAAR1PLAAT3
SCHEMBL5182649 0.89 HDAC1 (0.55) ALDH1A1FFAR1PDPK1TAAR1PLAAT3
Benzylacetone SCHEMBL27750721 0.87 ALDH1A1 (0.72) ALDH1A1FFAR1PDPK1PLAAT3PLAAT5
SCHEMBL11638365 0.86 HDAC1 (0.56) ALDH1A1FFAR1PDPK1TAAR1HDAC1
SCHEMBL2652762 0.85 MAOB (0.45) ALDH1A1FFAR1PDPK1PLAAT3PLAAT5
SCHEMBL7332151 0.84 FFAR1 (0.57) FFAR1PDPK1TAAR1PLAAT3PLAAT5
SCHEMBL10912165 0.83 ALDH1A1 (0.77) ALDH1A1FFAR1HDAC1MAPT
SCHEMBL117230 0.82 FFAR1 (0.73) FFAR1PDPK1TAAR1PLAAT3PLAAT5
SCHEMBL11801516 0.82 FFAR1 (0.55) FFAR1PDPK1TAAR1PLAAT3PLAAT5
SCHEMBL2953957 0.82 ALDH1A1 (0.59) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 WO disclosed
US-11793823-B2 Compounds and pharmaceutical uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-10-24 US disclosed
US-11793823-B2 Compounds and pharmaceutical uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-10-24 US disclosed
CN-111655700-B Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors 勃林格殷格翰国际有限公司 2023-07-18 CN disclosed
EP-3746451-B1 BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-07-12 EP disclosed
EP-3746451-B1 BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-07-12 EP disclosed
CN-115836062-A Compound and medical application thereof 心悦生医股份有限公司 2023-03-21 CN disclosed
EP-4139275-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2023-03-01 EP disclosed
US-20220218730-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2022-07-14 US disclosed
US-11254688-B2 Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-02-22 US disclosed
US-7166603-B2 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
US-7166603-B2 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
EP-1656141-A1 TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS MERCK SHARP & DOHME LTD. (GB) 2006-05-17 EP disclosed
WO-2005108362-A1 (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2005-11-17 WO disclosed
WO-2005013985-A1 TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS MERCK SHARP & DOHME LIMITED (GB) 2005-02-17 WO disclosed
WO-2005009392-A2 DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-03 WO disclosed
EP-0114374-B1 SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES BAYER AG (DE) 1986-07-23 EP disclosed
US-4563458-A CIRCULATORY SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1986-01-07 US disclosed
EP-0114374-A1 Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines BAYER AG (DE) 1984-08-01 EP disclosed
US-4160036-A ADRENERGIC STIMULANTS ALLEN & HANBURYS LIMITED (GB) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218730-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF HRH4, OR10J3, CYP3A5 ALDH1A1 654/4885FFAR1 2707/4885PDPK1 4400/4885
US-11254688-B2 Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors MBOAT4, ADIPOR1, GIPR ALDH1A1 461/4885FFAR1 147/4885PDPK1 1081/4885
US-11793823-B2 Compounds and pharmaceutical uses thereof HRH4, OR10J3, CYP3A5 ALDH1A1 654/4885FFAR1 2707/4885PDPK1 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.